6932 Stock Overview
Mercury Biopharmaceutical Corporation engages in the development of drugs for unmet needs in Taiwan.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Mercury Biopharmaceutical Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$13.90 |
| 52 Week High | NT$27.35 |
| 52 Week Low | NT$13.55 |
| Beta | 0 |
| 1 Month Change | -17.26% |
| 3 Month Change | -20.11% |
| 1 Year Change | -46.44% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 9.88% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6932 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | -9.2% | -0.3% | 1.1% |
| 1Y | -46.4% | 2.2% | 28.2% |
Return vs Industry: 6932 underperformed the TW Pharmaceuticals industry which returned 2.2% over the past year.
Return vs Market: 6932 underperformed the TW Market which returned 28.2% over the past year.
Price Volatility
| 6932 volatility | |
|---|---|
| 6932 Average Weekly Movement | 6.6% |
| Pharmaceuticals Industry Average Movement | 3.9% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in TW Market | 8.8% |
| 10% least volatile stocks in TW Market | 2.3% |
Stable Share Price: 6932's share price has been volatile over the past 3 months.
Volatility Over Time: 6932's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of TW stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | 16 | n/a | merdury.com |
Mercury Biopharmaceutical Corporation engages in the development of drugs for unmet needs in Taiwan. The company develops StackDose platform, a drug development platform to produce new dosage forms with precise time-controlled dissolution, precise site absorption, and various dosage adjustments to enhance the bio-availability of active pharmaceutical ingredients to reduce the dosage of drugs and its side effects. It develops drugs for treating erectile dysfunction, pulmonary hypertension, sleep disorder, benign prostatic hyperplasia, angina pectoris, migraine, anti-hypertension, and analgesic.
Mercury Biopharmaceutical Corporation Fundamentals Summary
| 6932 fundamental statistics | |
|---|---|
| Market cap | NT$5.78b |
| Earnings (TTM) | -NT$43.82m |
| Revenue (TTM) | NT$1.03m |
5,597x
P/S Ratio-132.0x
P/E RatioIs 6932 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6932 income statement (TTM) | |
|---|---|
| Revenue | NT$1.03m |
| Cost of Revenue | NT$441.00k |
| Gross Profit | NT$592.00k |
| Other Expenses | NT$44.41m |
| Earnings | -NT$43.82m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.11 |
| Gross Margin | 57.31% |
| Net Profit Margin | -4,241.63% |
| Debt/Equity Ratio | 10.7% |
How did 6932 perform over the long term?
See historical performance and comparison